Dupixent® (dupilumab) Recommended for EU Approval by the …
WEB1 day ago · DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe ...
Dupixent® (dupilumab) Recommended for EU Approval by the …
WEB17 hours ago · The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
WEBDupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial. Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with ...
Press Release: Dupixent recommended for EU approval by the …
WEB1 day ago · Dupixent is already approved in the EU for certain adults and adolescents aged 12 years and older with EoE. The positive CHMP opinion is supported by a two-part (Part A and B) EoE KIDS phase 3...
Dupixent® (dupilumab) Recommended for EU Approval by the …
WEB17 hours ago · Published. Sep 20, 2024 7:45am EDT. Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo,...
Dupixent® (dupilumab) Approved in the U.S. as First and Only …
WEBSep 13, 2024 · The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of type 2 inflammation that play a major role in multiple related and often co-morbid diseases.
Dupixent® late-breaking data from NOTUS confirmatory phase 3 …
WEBMay 20, 2024 · NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
FDA approves new eczema drug Dupixent | FDA - U.S. Food and …
WEBThe U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose...
Dupixent® - Pivotal Trial Results - Sanofi
WEBMar 23, 2006 · Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial. First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo.
Dupixent® (dupilumab) U.S. Label Updated with Data Further …
WEBJan 16, 2024 · Dupixent, which was invented using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.